trending Market Intelligence /marketintelligence/en/news-insights/trending/1oR-tuKDX6puhNL09fwYMQ2 content esgSubNav
In This List

Hyundai Pharm seeks approval for Acerus' testosterone drug in South Korea

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Hyundai Pharm seeks approval for Acerus' testosterone drug in South Korea

Hyundai Pharmaceutical Co. Ltd. filed for marketing approval with the Ministry of Food and Drug Safety in South Korea for Acerus Pharmaceuticals Corp.'s Natesto, a testosterone deficiency drug.

The company had acquired an exclusive license to market Natesto in South Korea from Acerus in December 2016.

If approved, Natesto will be the first and only testosterone nasal gel indicated for the treatment of low testosterone in South Korea.